McKesson Corporation

(New York Stock Exchange)
Back to all articles
Bullish +65

McKesson stock faces earnings test as analysts see profit growth

Earnings report AI-generated analysis

πŸ“… McKesson is scheduled to report fiscal second-quarter 2027 results after the market close on Wednesday, November 4.

πŸ’° Analysts expect quarterly diluted earnings per share to rise to $10.69, up 8.4% from the year-earlier period of $9.86.

🎯 Management targets adjusted fiscal 2027 earnings per share in the range of $44.20 to $45.00.

πŸ“ˆ McKesson has exceeded Wall Street's EPS estimates in each of its last four quarterly reports.

πŸ’΅ The company reported first-quarter revenue of $105.4 billion and adjusted EPS of $9.93, beating analyst estimates.

πŸ” Investors are assessing whether recent earnings momentum can continue into the second half of the fiscal year.

πŸ“‰ A result above consensus could reinforce the earnings narrative, while a weaker outlook could impact longer-term guidance.

🏒 The pharmaceutical distributor is focusing on the development of its core business during this reporting period.

Bullish Signals
  • McKesson has exceeded Wall Street's EPS estimates in each of its last four quarterly reports, demonstrating consistent outperformance.
  • The company reported first-quarter revenue of $105.4 billion and adjusted EPS of $9.93, both surpassing cited Wall Street estimates.
  • Analysts project a significant 8.4% year-over-year increase in diluted earnings per share to $10.69 for the upcoming quarter.
  • Management has set a clear target range for adjusted fiscal 2027 earnings per share between $44.20 and $45.00, indicating confidence in profitability.
Full Analysis
McKesson Corporation is preparing to release its fiscal second-quarter 2027 earnings report on Wednesday, November 4, following the market close. The pharmaceutical distributor enters this reporting period with a strong momentum from its first quarter, having previously exceeded Wall Street's earnings per share (EPS) estimates in each of its last four quarterly reports. Analysts project that McKesson will report diluted EPS of $10.69 for the quarter, representing an 8.4% increase compared to the same period a year ago. Management has set a specific target range for adjusted fiscal 2027 earnings per share between $44.20 and $45.00, which investors will scrutinize alongside the company's full-year guidance. The upcoming results are critical as they serve as the next major catalyst for McKesson's investment case. Market participants are closely watching whether the company can sustain its recent profit growth trajectory and if management adjusts its outlook based on the quarterly performance. The stock recently traded at 885.00 euros, reflecting investor anticipation of the earnings release. McKesson's first quarter provided a solid operating benchmark with revenue of $105.4 billion and adjusted EPS of $9.93, both surpassing analyst expectations. This consistent outperformance has raised the bar for the November update, where any deviation from consensus could significantly impact the company's valuation and longer-term guidance narrative.